Kala Pharmaceuticals Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
The Company granted stock options to purchase up to an aggregate of
26,000 shares of
About
Kala is a biopharmaceutical company focused on the development and
commercialization of therapeutics using its proprietary AMPPLIFY™
mucus-penetrating particle (MPP) Drug Delivery Technology, with an
initial focus on the treatment of eye diseases. Kala has applied the
AMPPLIFY Drug Delivery Technology to a corticosteroid, loteprednol
etabonate (LE), designed for ocular applications, resulting in recently
approved INVELTYS® for the treatment of inflammation and pain
following ocular surgery and its lead product candidate, KPI-121 0.25%,
for the temporary relief of the signs and symptoms of dry eye disease,
for which a target action date under the Prescription Drug User Fee Act
(PDUFA) has been set by the United States Food and Drug
Administration (
View source version on businesswire.com: https://www.businesswire.com/news/home/20190517005055/en/
Source:
For Kala Pharmaceuticals, Inc.
Investors
Michael Schaffzin,
212-362-1200
michael@sternir.com
or
Media
Kari
Watson, 781-235-3060
kwatson@macbiocom.com